Cerasee / Bitter Melon (Momordica charantia): Diabetes Claims & Evidence

In many Caribbean communities, cerasee commonly refers to Momordica charantia, also known as bitter melon or bitter gourd. Common names can vary by place, so we still verify the species before tying a product to research.

Quick answer

Human trials of Momordica charantia for blood-sugar control have produced conflicting results. Some meta-analyses report modest improvements, while others find no reliable benefit over placebo. The evidence is not strong enough to use cerasee as a replacement for diabetes treatment.

Why the studies disagree

Different trials have used different plant parts, extracts, doses, durations, and comparison groups. A 2019 meta-analysis reported improvements in fasting glucose and HbA1c but rated the primary evidence low to very low quality. A 2024 meta-analysis found no significant effect on fasting glucose or HbA1c in change-score analyses and emphasized that the trials were small and short.

Evidence strength

Norene’s Farmacy rating: MIXED HUMAN EVIDENCE / LOW CERTAINTY.

Safety and diabetes medication

Because bitter melon may affect glucose, combining concentrated preparations with insulin or glucose-lowering medication can complicate blood-sugar management. Anyone using diabetes medication should discuss concentrated cerasee or bitter-melon products with their healthcare professional.

Sources

Peter EL, et al. Journal of Ethnopharmacology. 2019 systematic review and meta-analysis. PubMed PMID 30385422.

Laczkó-Zöld E, et al. 2024 systematic review and meta-analysis of randomized trials. PubMed PMID 38274207.

Dr. Village Reports is educational journalism and product guidance, not medical advice.